PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11929024

Brachytherapy dose-volume histogram computations using optimized stratified sampling methods.

K Karouzakis·M Lahanas·N Milickovic·S Giannouli·D Baltas·N Zamboglou
View original source ↗Export metadata ↓

Abstract

A stratified sampling method for the efficient repeated computation of dose-volume histograms (DVHs) in brachytherapy is presented as used for anatomy based brachytherapy optimization methods. The aim of the method is to reduce the number of sampling points required for the calculation of DVHs for the body and the PTV. From the DVHs are derived the quantities such as Conformity Index COIN and COIN integrals. This is achieved by using partial uniform distributed sampling points with a density in each region obtained from a survey of the gradients or the variance of the dose distribution in these regions. The shape of the sampling regions is adapted to the patient anatomy and the shape and size of the implant. For the application of this method a single preprocessing step is necessary which requires only a few seconds. Ten clinical implants were used to study the appropriate number of sampling points, given a required accuracy for quantities such as cumulative DVHs, COIN indices and COIN integrals. We found that DVHs of very large tissue volumes surrounding the PTV, and also COIN distributions, can be obtained using a factor of 5-10 times smaller the number of sampling points in comparison with uniform distributed points.

Explore related subjects

BrachytherapyHumansModels, StatisticalRadiometrySoftwareJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Karouzakis, M Lahanas, N Milickovic, S Giannouli, D Baltas, N Zamboglou. 2002. Brachytherapy dose-volume histogram computations using optimized stratified sampling methods.. https://doi.org/10.1118/1.1450131

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III).

We report the long-term outcome of 225 patients who failed gamma-brachytherapy for in-stent restenosis. Total adverse events, target vessel revascularization, and myocardial infarction were higher after repeat percutaneous coronary intervention versus coronary artery bypass grafting. Therefore, coronary artery bypass grafting may be the preferable first-line therapy in these patients until other therapies (i.e., drug-eluting stents) are available. Shorter time from brachytherapy to radiation failure and late thrombosis after brachytherapy were independent predictors of adverse events.

Brachytherapy↗
PubMed2003

A chronological database to support outcomes research in prostate cancer.

PURPOSE: To outline the process for developing a data management system for patients with prostate cancer. METHODS AND MATERIALS: Between 1997 and 2002, several generations of a working database using a Microsoft Access platform were developed for the tracking of patients with prostate cancer. The database evolved to include both the management of clinical practice and outcomes research. A chronological data system lists events by their date and value. Algorithms for data exporting can access these lists in defined ways to mine for specific parameters. RESULTS: The most recent working model of our database was implemented with over 2000 patients entered and over 250,000 rows of data. It is utilized by the entire staff and is central for processing prostate cancer data within the department. Outcome studies have been performed using the system, and data export algorithm development remains ongoing. CONCLUSIONS: This work demonstrates that functional database systems are possible for large clinics treating patients with prostate cancer. The ability to maintain up-to-the-minute data variables is vital not only for unbiased outcomes analysis, but for patient flow and care. Future systems will migrate to web platforms.

Brachytherapy↗
PubMed2003

Custom-made "Nag" eye plaques for 125I brachytherapy.

PURPOSE: To report our experience in treating medium-size ocular melanomas with custom-made "Nag" eye plaques. METHODS: Seventy-eight patients with medium-size ocular melanomas were treated with plaques of 0.6-mm-thick, 18k gold with a radius of curvature of 12 mm to conform to the curvature of the eyeball. These plaques were custom-made in various sizes and shapes to encompass the base of the tumor and a 1-mm margin on all sides. Apertures in three wings of these plaques allowed sutures to be easily placed to hold the plaques onto the sclera. A dose of 100 Gy (before TG-43) or 85 Gy (after TG-43) was delivered with (125)I in 4 days. The dose was prescribed to the periphery of tumor at the level of tumor apex to ensure that the entire tumor volume received at least this dose. RESULTS: The median follow-up was 49 months (range 8-112 months). The progression-free survival (Kaplan-Meier method), overall survival, and disease-specific survival at 5 years were 93%, 86%, and 97%, respectively. Fifty of 78 (64%) patients retained useful visual acuity (20/200 or better). Thirty-one of 78 (40%) patients developed retinopathy or papillopathy. In the subgroup of 22 patients with tumor distance < or =2 mm from optic disc or macula, 12 patients (54%) developed retinopathy or papillopathy. Only 7 of these patients (32%) had useful vision (20/200 or better). Short distance to optic disc or macula was associated with significantly poor visual acuity and moderate to severe retinopathy or papillopathy (ANOVA, p = 0.004 and p = 0.002, respectively). CONCLUSION: Our experience suggests that custom-made Nag plaque brachytherapy can control medium-size choroidal melanoma and that a 1-mm, rather than the standard 2-mm, minimum margin is sufficient when this plaque and prescription methods are used. Patients with tumors close (< or =2 mm) to optic disc or macula have a significantly poorer visual outcome.

Brachytherapy↗